Definition
Nociceptin is a 17 amino acid opioid-like peptide that was identified as a natural ligand of the orphan opioid receptor ORL1 (also referred to as OP4). Reinscheid et al., called the same peptide orphanin FQ to signify that it is a ligand for ORL1 with an N-terminal phenylalanine and a C-terminal glutamine 1.
Related peptides
The prepronociceptin gene also encodes another peptide, termed nocistatin. Nocistatin blocks allodynia and hyperalgesia induced by Nociceptin and attenuates pain evoked by prostaglandin E2. Nocistatin does not bind to the Nociceptin receptor. Nociceptin and nocistatin may play opposite roles in pain transmission 2. Nociceptin is related to dynorphin A, a peptide 17-mer ligand of the -opioid receptor. Dynorphin A also binds ORL1 but with 100-fold lower affinity than nociceptin . Orphanin FQ2 is another biologically active peptide 17-mer processed from the same nociceptin precursor, prenociceptin 1.
Discovery
Civelli et al., in 1998, reported the discovery of a peptide ligand that shares some striking sequence similarity to the opioid peptides and named it Orphanin FQ or Nociceptin (OFQ/NOC) 3.
Structural Characteristics
Nociceptin is a 17 amino acid neuropeptide. The full pharmacophore site for nociceptin has the phenyl ring of Phe1 on top of that for Phe4. The first turn of the helix places Phe4 over Ala7 and Arg8 followed by the second turn of the helix with another Ala-Arg pair, Ala11 and Arg12. This fold causes the two pairs of alanine-arginine residues, both of which appear to be crucial to activity, to lie on top of one another. This finding suggests that nociceptin when folded in this fashion interacts with ORL1 via both hydrophobic residues and positively charged residues. As mentioned above, it also appears that the hydrogen bonding potential of the arginine guanidinium group and not only its positive charge plays a role in the activity of nociceptin 1.
Nociceptin Fragments
The nociceptin N-terminal fragments, (1–11) and (1–13), are active with a potency higher than nociceptin and comparable to nociceptin, respectively. The nociceptin (1–7) fragment had no effect on capsaicin-induced nociception. Nociceptin (1–11) is approximately 2.0-fold more potent than naturally occurring peptide nociceptin, and 10-fold more active than intraplantar morphine. Nociceptin and the N-terminal fragment (1–13) possess a local peripheral antinociceptive action, which may be mediated by peripheral ORL1 receptors. In addition, the antinociceptive action and inhibition of capsaicin-induced desenitization by nociceptin, nociceptin (1–11) and (1–13), may involve distinct mechanisms at the level of the peripheral nerve terminal 4.
The minimal fragment sequence required to fully activate the nociceptin (NC) receptor, namely NC(1-13)-NH2, was used as template for the design of a series of new compounds. Changes were made in the N-terminal tetrapeptide Phe-Gly-Gly-Phe, which has been shown to be essential for receptor occupation and activation. The new compounds were tested for their ability to inhibit the electrically evoked contraction of the mouse vas deferens, a pharmacological preparation sensitive to NC. Results obtained indicate that (a) the replacement of Gly2 or Gly3 with an aromatic residue (Phe) of L or D chirality eliminates the ability of the peptide to occupy the NC receptor; (b) the distance between Phe1 and Phe4 of NC appears to be critical, since any alteration of it leads to a marked decrease or a total elimination of biological activity; and (c) the insertion of a pseudopeptide bond between Phe1 and Gly2 maintains affinity but eliminates the ability of the peptide to activate the NC receptor and leads to antagonism. The peptide [Phe1?(CH2-NH)Gly2]-NC(1-13)-NH2 acts as a selective NC receptor antagonist and is inactive on opioid receptors 5.
Mechanism of action
Meunier et al., (1995) and Reinscheid et al., (1995) have shown that nociceptin is a physiological ligand for an orphan heterotrimeric GTP-binding protein6,7. This protein was identified originally as the G-protein-coupled receptor LC1328. Mollereau et al., (1994) have cloned the human nociceptin receptor, a G-protein-coupled receptor of 370 amino acids most closely related to opioid receptors. The receptor is known also as NOCIR [nociceptin receptor] OPRL1 or ORL1 [opioid receptor-like-1], OP4, or NOP [non-classical opioid receptor] 9.
Functions
Nociceptin signaling through ORL1 elicits many of the same responses induced by opioid signaling through the opioid receptors. Nociceptin causes inhibition of adenylyl cyclase, activation of potassium channels, inhibition of calcium channels, mobilization of intracellular calcium, and activation of mitogen-activated protein kinase. These effects indicate that, similar to opioids, nociceptin has an inhibitory effect on synaptic transmission in the nervous system, acting to reduce the secretion of neurotransmitters. Consistent with its cellular effects, nociceptin inhibits the release of glutamate, -Aminobutyric acid, acetylcholine, tachykinin, and noradrenaline neurotransmitters. Based on their distribution in the brain and spinal cord, nociception and its receptor may be involved in a wide range of functions, including learning, memory, attention, and emotion. Nociceptin is also implicated in various sensory processes such as perception of pain, visual, auditory, and olfactory functions1.
References
1.Orsini MJ, Nesmelova I, Young HC, Hargittai B, Beavers MP, Liu J, Connolly PJ, Middleton SA, Mayo KH (2005). The Nociceptin Pharmacophore Site for Opioid Receptor Binding Derived from the NMR Structure and Bioactivity Relationships. J. Biol. Chem., 280(9):8134-8142.
2. Okuda-Ashitaka E, Minami T, Tachibana S, Yoshihara Y, Nishiuchi Y, Kimura T, Ito S (1998). Nocistatin, a peptide that blocks Nociceptin action in pain transmission. Nature, 392(6673):286-289.
3.Civelli O, Nothacker HP, Reinscheid R (1998). Reverse physiology: discovery of the novel neuropeptide, orphanin FQ/nociceptin. Crit Rev Neurobiol., 12(3):163-176.
4.Sakurada T, Komatsu T, Moriyama T, Sasaki M, Sanai K, Orito T, Sakurada C, Sakurada S (2005). Effects of intraplantar injections of nociceptin and its N-terminal fragments on nociceptive and desensitized responses induced by capsaicin in mice. Peptides, 26(12):2505-2512.
5.Calo G, Guerrini R, Bigoni R, Rizzi A, Bianchi C, Regoli D, Salvadori S (1998). Structure-activity study of the Nociceptin(1-13)-NH2 n-terminal tetrapeptide and discovery of a nociceptin receptor antagonist. J medi chem., 41(18):3360-3366.
6.Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butour JL, Guillemot JC, Ferrara P, Monsarrat B (1995). Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature, 377(6549):532-535.
7.Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FJ Jr, Civelli O (1995). Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science, 270(5237):792-794.
8.Bunzow JR, Saez C, Mortrud M, Bouvier C, Williams JT, Low M, Grandy DK (1994). Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. FEBS Letters., 347(2-3): 284-288.
9.Mollereau C, Parmentier M, Mailleux P, Butour JL, Moisand C, Chalon P, Caput D, Vassart G, Meunier JC (1994). ORL1, a novel member of the opioid receptor family: cloning, functional expression and localization. FEBS Letters., 341:33-38
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Tuesday, November 17, 2009
NF-kB/Transcription Factors Related Peptides
Definition
NF-?B, a eukaryotic transcription factor plays an important role in inflammation, autoimmune response, cell proliferation, and apoptosis by regulating the expression of genes involved in these processes. It consists of homo- or heterodimers of different subunits, which belong to a family of Rel/NF-?B proteins1.
Related Peptides
The Rel/NF- B transcription factor family is comprised of several structurally-related proteins that exist in organisms from insects to humans. The vertebrate family includes five cellular proteins: c-Rel, RelA, RelB, p50/p105, and p52/p100 2.
Discovery
NF- B was originally identified as a B-cell nuclear factor by Sen and Baltimore in 1986 3.
Structural Characteristics
Structurally, Rel/NF- B proteins are related through an approximately 300 amino acid domain, called the Rel homology (RH) domain, which contains sequences essential for dimerization, DNA binding, and nuclear transport. C-terminal to the RH domain, one class of Rel proteins (c-Rel, RelA and RelB) has transactivation domains. The second class of Rel proteins can exist either as short, active DNA-binding proteins (p50 and p52) or inactive proteins (p105 and p100), which contain additional C-terminal inhibitory domains related to the I B proteins. All I B proteins have a core domain, which consists of multiple, ankryin repeats necessary for protein ? protein interactions with Rel proteins. The best-studied I B protein, I B , has an N-terminal regulatory domain containing the two Serine residues that are phosphorylated by IKK and lysine residues to which ubiquitin is conjugated 2.
Mode of Action
NF-?B activation is stimulated by a pro-oxidative cell status, especially by an increased presence of H2O21. As homodimers or heterodimers, vertebrate Rel/NF- B proteins bind to a set of related DNA target sites, collectively called B sites, and directly regulate gene expression. Thus, even a single cell can have a combinatorially diverse array of dimeric complexes, the most common of which is called NF- B and consists of a p50/RelA heterodimer. The different Rel/NF- B proteins show distinct abilities to form dimers, distinct preferences for different B sites, and distinct abilities to bind to I B inhibitor proteins. Thus, different Rel/NF- B complexes can be induced in different cell types and by distinct signals, can interact in distinct ways with other transcription factors and regulatory proteins, and can regulate the expression of distinct gene sets. These types of considerations are likely to be responsible for the sometimes opposite effects of Rel/NF- B complexes in different cell types.
The regulation of Rel/NF- B transcription complexes is now known in some detail. In most cell types, these complexes exist in a latent, inactive form in the cytoplasm where they are bound to any of several related I B inhibitor proteins. The vertebrate I B proteins include I B , I B , I B , I B , p105, p100, and Bcl-3, among others. Although activation of Rel/NF- B proteins can follow a variety of pathways, the most common proximal step appears to occur via induced phosphorylation of I B at two N-terminal Ser residues by a large I B kinase complex (IKK), and phosphorylation of I B leads to its degradation by the proteasome. The freed Rel/NF- B complex can then enter the nucleus and bind to DNA 2.
Functions
Rel/NF- B transcription factors are induced in response to many signals that lead to cell growth, differentiation, inflammatory responses, the regulation of apoptosis, and neoplastic transformation. The pivotal role played by these transcription factors is illustrated not only by the great diversity of genes that they regulate, but also by the large variety of stimuli that lead to their activation. In diverse cell types, Rel/NF-kappaB transcription factors have been shown to have a role in regulating the apoptotic program, either as essential for the induction of apoptosis or, perhaps more commonly, as blockers of apoptosis. Whether Rel/NF-kappaB promotes or inhibits apoptosis appears to depend on the specific cell type and the type of inducer 2.
References
1.Pande V, Ramos MJ (2005). NF- kappaB in Human Disease: Current Inhibitors and Prospects for De Novo Structure Based Design of Inhibitors. Curr Med Chem., 12(3):357-374.
2.Barkett M, Gilmore TD (1999). Control of apoptosis by Rel/NF-?B transcription factors. Oncogene, 18(49):6910-6924
3.Sen R, Baltimore D (1986) .Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell, 46(5):705-716.

For more detail regarding Peptide please visit here : Custom Peptide Synthesis
NF-?B, a eukaryotic transcription factor plays an important role in inflammation, autoimmune response, cell proliferation, and apoptosis by regulating the expression of genes involved in these processes. It consists of homo- or heterodimers of different subunits, which belong to a family of Rel/NF-?B proteins1.
Related Peptides
The Rel/NF- B transcription factor family is comprised of several structurally-related proteins that exist in organisms from insects to humans. The vertebrate family includes five cellular proteins: c-Rel, RelA, RelB, p50/p105, and p52/p100 2.
Discovery
NF- B was originally identified as a B-cell nuclear factor by Sen and Baltimore in 1986 3.
Structural Characteristics
Structurally, Rel/NF- B proteins are related through an approximately 300 amino acid domain, called the Rel homology (RH) domain, which contains sequences essential for dimerization, DNA binding, and nuclear transport. C-terminal to the RH domain, one class of Rel proteins (c-Rel, RelA and RelB) has transactivation domains. The second class of Rel proteins can exist either as short, active DNA-binding proteins (p50 and p52) or inactive proteins (p105 and p100), which contain additional C-terminal inhibitory domains related to the I B proteins. All I B proteins have a core domain, which consists of multiple, ankryin repeats necessary for protein ? protein interactions with Rel proteins. The best-studied I B protein, I B , has an N-terminal regulatory domain containing the two Serine residues that are phosphorylated by IKK and lysine residues to which ubiquitin is conjugated 2.
Mode of Action
NF-?B activation is stimulated by a pro-oxidative cell status, especially by an increased presence of H2O21. As homodimers or heterodimers, vertebrate Rel/NF- B proteins bind to a set of related DNA target sites, collectively called B sites, and directly regulate gene expression. Thus, even a single cell can have a combinatorially diverse array of dimeric complexes, the most common of which is called NF- B and consists of a p50/RelA heterodimer. The different Rel/NF- B proteins show distinct abilities to form dimers, distinct preferences for different B sites, and distinct abilities to bind to I B inhibitor proteins. Thus, different Rel/NF- B complexes can be induced in different cell types and by distinct signals, can interact in distinct ways with other transcription factors and regulatory proteins, and can regulate the expression of distinct gene sets. These types of considerations are likely to be responsible for the sometimes opposite effects of Rel/NF- B complexes in different cell types.
The regulation of Rel/NF- B transcription complexes is now known in some detail. In most cell types, these complexes exist in a latent, inactive form in the cytoplasm where they are bound to any of several related I B inhibitor proteins. The vertebrate I B proteins include I B , I B , I B , I B , p105, p100, and Bcl-3, among others. Although activation of Rel/NF- B proteins can follow a variety of pathways, the most common proximal step appears to occur via induced phosphorylation of I B at two N-terminal Ser residues by a large I B kinase complex (IKK), and phosphorylation of I B leads to its degradation by the proteasome. The freed Rel/NF- B complex can then enter the nucleus and bind to DNA 2.
Functions
Rel/NF- B transcription factors are induced in response to many signals that lead to cell growth, differentiation, inflammatory responses, the regulation of apoptosis, and neoplastic transformation. The pivotal role played by these transcription factors is illustrated not only by the great diversity of genes that they regulate, but also by the large variety of stimuli that lead to their activation. In diverse cell types, Rel/NF-kappaB transcription factors have been shown to have a role in regulating the apoptotic program, either as essential for the induction of apoptosis or, perhaps more commonly, as blockers of apoptosis. Whether Rel/NF-kappaB promotes or inhibits apoptosis appears to depend on the specific cell type and the type of inducer 2.
References
1.Pande V, Ramos MJ (2005). NF- kappaB in Human Disease: Current Inhibitors and Prospects for De Novo Structure Based Design of Inhibitors. Curr Med Chem., 12(3):357-374.
2.Barkett M, Gilmore TD (1999). Control of apoptosis by Rel/NF-?B transcription factors. Oncogene, 18(49):6910-6924
3.Sen R, Baltimore D (1986) .Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell, 46(5):705-716.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Neurotrophic Factors
Definition
Neurotrophic factors are small proteins that exert survival-promoting and trophic (derived from the Greek meaning "to nourish") actions on neuronal (or nerve) cells1.
Related Peptides
The neurotrophic factors, a subclass of growth factors, act on neurons as well as other non-neuronal cells. This subclass of factors contains at least three distinct families: the neurotrophins (e.g., NGF: brain-derived neurotrophic factor, BDNF: and neurotrophins NT-3 and NT-4/5); the neuropoietic cytokines (e.g., ciliary neurotrophic factor, CNTF); and the fibroblast growth factors (e.g., acidic and basic FGF). The members of these families of neurotrophic factors demonstrate significant (50% or more) homology and have affinities for particular classes of receptors.
Proteins with well-documented neurotrophic activity:
Acidic fibroblast growth factor (aFGF)
Basic fibroblast growth factor (bFGF)
Brain-derived neurotrophic factor (BDNF)
Ciliary neurotrophic factor (CNTF)
Interleukin 1, 3 and 6 (IL-1, 3, 6)
Neurotrophin-3 (NT-3)
Neurotrophin-4/5 (NT-4/5)
Nerve growth factor (NGF)
Glial-derived neurotrophic factor (GDNF)
Proteins with putative neurotrophic activity:
Cholinergic neuronal differentiation factor (CDF)
Epidermal growth factor (EGF)
Heparin binding neurotrophic factor (HBNF)
Insulin
Insulin like growth factors (IGFs)
Protease nexin I and II
Transforming growth factor alpha (TGFalpha) 1.
Discovery
The discovery of nerve growth factor (NGF) by Rita Levi-Montalcini in the 1950s represents an important milestone in the processes that led to modern cell biology. NGF was the first growth factor identified, for its action on the morphological differentiation of neural-crest-derived nerve cells. Later, its effect on neuronal cells of the peripheral and central nervous system, and on several non-neuronal cells was also determined. Thus, Levi-Montalcini's work on NGF represents, as acknowledged by the Nobel Prize Assembly in its press release of 13 October 1986, ‘a fascinating example of how a skilled observer can create a concept out of apparent chaos’ 2, 3.
Structural Characteristics
These molecules are generally small, soluble proteins with molecular weights between 13-24kDa and are often active as homodimers1.
Mode of Action
Neurotrophic factors bind to a low affinity receptor (p75) and to a family of closely related high affinity glycoprotein tyrosine receptor kinases (Trk molecules). The receptor topology for the neuropoietic cytokines is very different. The transduction pathway for CNTF, for example, involves a tyrosine kinase, but the receptor itself is not a tyrosine kinase. The CNTF receptor consists of a complex of three subunits, only one of which directly binds CNTF, and the tyrosine kinase JAK/TYK, which associates with the CNTF receptor complex on the cytosolic side of the plasma membrane. The binding of the FGFs on the other hand is different from the other neurotrophic factors in that it involves a low affinity binding site related to heparin sulfate and a high affinity receptor that contains a tyrosine kinase. Unlike most known receptor molecules, all these tyrosine kinase receptors possess only one transmembrane domain. The first step in their activation by growth factors always involves receptor oligomerization, which seems to be the initial signal transduction event that leads to tyrosine kinase activation. Not only are the receptor mechanisms comparable for the various neurotrophic factors, but also the intracellular signaling pathways are very similar, even for such diverse molecules as NGF, CNTF and FGF. Thus, a large group of diverse factors act on distinct receptors, leading to similar intracellular molecular changes which can profoundly impact neuron development and survival.
Functions
During development, these factors play a critical role in mediating the ability of a target (e.g., skeletal muscle) of a neuron (e.g., spinal cord motor neuron) to prevent the death of the nerve cell. In addition to these effects on neuronal survival, neurotrophic factors play a critical role in the "quality of life" of neurons. Neurotrophic factors regulate growth of neurons, associated metabolic functions such as protein synthesis, and the ability of the neuron to make the neurotransmitters that carry chemical signals which allow the neuron to communicate with other neurons or with other targets (muscles, glands, etc.). Because of these actions, neurotrophic factors play a significant role in the maintenance of neuronal function throughout an individual's entire lifetime1.
References
1.Lipton P, Kalil R. (1995). Neurotrophic Factors - An Overview. Promega Notes Magazine., 50:.18-21.
2.Aloe L. (2004). Rita Levi-Montalcini: the discovery of nerve growth factor and modern neurobiology. Trends in Cell Biology. 14(7):395-399.
3.Cohen, S., Levi-Montalcini, R. Hamburger.(1954). A nerve growth stimulating factor isolated from sarcoma as 37 and 180. PNAS., 1 40(10): 1014–1018.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Neurotrophic factors are small proteins that exert survival-promoting and trophic (derived from the Greek meaning "to nourish") actions on neuronal (or nerve) cells1.
Related Peptides
The neurotrophic factors, a subclass of growth factors, act on neurons as well as other non-neuronal cells. This subclass of factors contains at least three distinct families: the neurotrophins (e.g., NGF: brain-derived neurotrophic factor, BDNF: and neurotrophins NT-3 and NT-4/5); the neuropoietic cytokines (e.g., ciliary neurotrophic factor, CNTF); and the fibroblast growth factors (e.g., acidic and basic FGF). The members of these families of neurotrophic factors demonstrate significant (50% or more) homology and have affinities for particular classes of receptors.
Proteins with well-documented neurotrophic activity:
Acidic fibroblast growth factor (aFGF)
Basic fibroblast growth factor (bFGF)
Brain-derived neurotrophic factor (BDNF)
Ciliary neurotrophic factor (CNTF)
Interleukin 1, 3 and 6 (IL-1, 3, 6)
Neurotrophin-3 (NT-3)
Neurotrophin-4/5 (NT-4/5)
Nerve growth factor (NGF)
Glial-derived neurotrophic factor (GDNF)
Proteins with putative neurotrophic activity:
Cholinergic neuronal differentiation factor (CDF)
Epidermal growth factor (EGF)
Heparin binding neurotrophic factor (HBNF)
Insulin
Insulin like growth factors (IGFs)
Protease nexin I and II
Transforming growth factor alpha (TGFalpha) 1.
Discovery
The discovery of nerve growth factor (NGF) by Rita Levi-Montalcini in the 1950s represents an important milestone in the processes that led to modern cell biology. NGF was the first growth factor identified, for its action on the morphological differentiation of neural-crest-derived nerve cells. Later, its effect on neuronal cells of the peripheral and central nervous system, and on several non-neuronal cells was also determined. Thus, Levi-Montalcini's work on NGF represents, as acknowledged by the Nobel Prize Assembly in its press release of 13 October 1986, ‘a fascinating example of how a skilled observer can create a concept out of apparent chaos’ 2, 3.
Structural Characteristics
These molecules are generally small, soluble proteins with molecular weights between 13-24kDa and are often active as homodimers1.
Mode of Action
Neurotrophic factors bind to a low affinity receptor (p75) and to a family of closely related high affinity glycoprotein tyrosine receptor kinases (Trk molecules). The receptor topology for the neuropoietic cytokines is very different. The transduction pathway for CNTF, for example, involves a tyrosine kinase, but the receptor itself is not a tyrosine kinase. The CNTF receptor consists of a complex of three subunits, only one of which directly binds CNTF, and the tyrosine kinase JAK/TYK, which associates with the CNTF receptor complex on the cytosolic side of the plasma membrane. The binding of the FGFs on the other hand is different from the other neurotrophic factors in that it involves a low affinity binding site related to heparin sulfate and a high affinity receptor that contains a tyrosine kinase. Unlike most known receptor molecules, all these tyrosine kinase receptors possess only one transmembrane domain. The first step in their activation by growth factors always involves receptor oligomerization, which seems to be the initial signal transduction event that leads to tyrosine kinase activation. Not only are the receptor mechanisms comparable for the various neurotrophic factors, but also the intracellular signaling pathways are very similar, even for such diverse molecules as NGF, CNTF and FGF. Thus, a large group of diverse factors act on distinct receptors, leading to similar intracellular molecular changes which can profoundly impact neuron development and survival.
Functions
During development, these factors play a critical role in mediating the ability of a target (e.g., skeletal muscle) of a neuron (e.g., spinal cord motor neuron) to prevent the death of the nerve cell. In addition to these effects on neuronal survival, neurotrophic factors play a critical role in the "quality of life" of neurons. Neurotrophic factors regulate growth of neurons, associated metabolic functions such as protein synthesis, and the ability of the neuron to make the neurotransmitters that carry chemical signals which allow the neuron to communicate with other neurons or with other targets (muscles, glands, etc.). Because of these actions, neurotrophic factors play a significant role in the maintenance of neuronal function throughout an individual's entire lifetime1.
References
1.Lipton P, Kalil R. (1995). Neurotrophic Factors - An Overview. Promega Notes Magazine., 50:.18-21.
2.Aloe L. (2004). Rita Levi-Montalcini: the discovery of nerve growth factor and modern neurobiology. Trends in Cell Biology. 14(7):395-399.
3.Cohen, S., Levi-Montalcini, R. Hamburger.(1954). A nerve growth stimulating factor isolated from sarcoma as 37 and 180. PNAS., 1 40(10): 1014–1018.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Neuropeptide Y (NPY), Analogs and Fragments
Definition
Neuromedins, smooth-muscle-stimulating peptides, are commonly divided into four groups: bombesin-like, kassinin-like, neurotensin-like and neuromedins U. These neuropeptides and their receptors are localized to all components of the HPA axis, the only exemption seems to be neurokinin B, which is not detected in the adenohypophysis 1.
Related Peptides
Nine neuromedins (B, B-30, B-32, C, K, L, N, U-8 and U-25) thus far identified in porcine spinal cord as the smooth-muscle stimulating peptides, are classified into four families; B-(bombesin-like), K-(kassinine-like), N-(neurotensin-like) and U-groups 2.
Discovery
Minamino et al., identified Neuromedin B, K, L, C, B-32, B-30, U-8, U-25, in porcine spinal cord, between 1983 and 1985 3. In 2008, Mori et al., isolated Neuromedin S, a novel neuropeptide of 36 amino acids, from rat brain as an endogenous ligand for the orphan G protein-coupled receptors FM-3/GPR66 and FM-4/TGR-1, identified to date as type-1 and type-2 neuromedin U (NMU) receptors, respectively. The peptide was designated neuromedin S (NMS) because it is specifically expressed in the suprachiasmatic nucleus of the hypothalamus 4.
Structural characteristics
Porcine neuromedin K has been identified by microsequencing as: Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH24. The sequence thus determined has been confirmed by synthesis. Neuromedin K has been found to have not only a remarkable sequence homology to kassinin and substance P, but also a prompt stimulant activity on guinea-pig ileum in a manner similar to that of substance P, suggesting that neuromedin K may be involved in neural transmission 6.
Novel mammalian tachykinin, designated "neuromedin L", has been isolated from porcine spinal cord by using bioassay for a tachykinin-like effect on contractility of smooth muscle preparation from guinea pig ileum. By microsequencing, the peptide has been determined to be His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2. This structure has been confirmed by synthesis. Neuromedin L is found to elicit a prompt stimulant activity on guinea pig ileum in a manner similar to that of substance P, and to have remarkable sequence homology to kassinin as well as neuromedin K, which was earlier identified as a mammalian tachykinin. These facts suggest that neuromedin L may participate in neural transmission in the same manner as other members of the mammalian tachykinin family, such as substance P and neuromedin K 7.
Sequence analyses and syntheses revealed that neuromedin U-8 is a novel octapeptide with a C-terminal amide structure, while U-25 contains the U-8 sequence at its C-terminus, preceded by paired Arg residues, implicating their biosynthetic relationship. Their potent uterus stimulating activity and hypertensive effect, as well as their unique C-terminal amide structure are indicative of their specialized physiological function 5.
Neuromedin C was obtained from a side fraction of neuromedin B. It is another decapeptide that exhibits a potent stimulant effect on the smooth muscle preparation of rat uterus. By microsequencing and synthesis, the amino acid sequence of the peptide has been identified as: Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2. This peptide is found to be identical with the carboxy-terminal subsequence [18-27] of gastrin releasing peptide, and to display a potent contractile activity on rat uterus in the characteristic manner of bombesin. These facts strongly suggest that the peptide may be a neuromediator in the neural communication systems of mammals 8.
Neuromedin S is structurally related to Neuromedin U. These peptides share a C-terminal core structure4.
Mode of Action
Two structurally related, G-protein-coupled receptors, FM-3 and FM-4, are specific and functional receptors for neuromedin U, designated NMU1 and NMU2, respectively. NMU1 is expressed predominantly in peripheral tissues, whereas NMU2 is more highly expressed in the central nervous system 9. Functional screening assays suggest that NmU-R1 and NmU-R2 of human and rodent origin are able to mediate intracellular Ca2+ signaling with potency in the nanomolar range. Activation of either hNmU-R1 or hNmU-R2 is also able to stimulate the release of arachidonic acid, most likely through a Ca2+-dependent activation of phospholipase A2 10. The receptor that interacts with the mammalian bombesin-related peptide neuromedin B (NMB) is ubiquitous in the gastrointestinal tract and central nervous system. Activation of the receptor for NMB stimulates phospholipase C and increases intracellular Ca2+ 11.
Functions
Neuromedins exert a manifold effect on HPA axis, and their action on the adrenal suggests their involvement in the regulation of growth, structure and function of the adrenal cortex. Neuromedins may exert both direct and indirect effects on the adrenal cortex. Direct effect is proven by the stimulation of mineralo- and glucocorticoid output by isolated or cultured adrenocortical cells and by mobilisation of intracellular [Ca2+]i. Indirect effects, on the other hand, may be mediated by ACTH, arginine-vasopressin, angiotensin II, catecholamines or by other regulatory substances of medullary origin 1.
References
1.Malendowicz LK (1998). Role of neuromedins in the regulation of adrenocortical function. Horm Metab Res., 30(6-7):374-383.
2.Minamino N, Sudoh T, Kangawa K, Matsuo H (1985). Neuromedins: novel smooth-muscle stimulating peptides identified in porcine spinal cord. Peptides, 6(3):245-248.
3.Minamino N, Kangawa K, Matsuo H (1983). Neuromedin B: a novel bombesin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun., 114(2):541-548.
4.Mori K, Miyazato M, Kangawa K (2008). Neuromedin S: discovery and functions. Results Probl Cell Differ.,46:201-212.
5.Minamino N, Sudoh T, Kangawa K, Matsuo H (1985). Neuromedins: novel smooth-muscle stimulating peptides identified in porcine spinal cord. Peptides, 6(3):245-248.
6.Kangawa K, Minamino N, Fukuda A, Matsuo H (1983). Neuromedin K: a novel mammalian tachykinin identified in porcine spinal cord. Biochem Biophys Res Commun., 114(2):533-540.
7.Minamino N, Kangawa K, Fukuda A, Matsuo H (1984). Neuromedin L: a novel mammalian tachykinin identified in porcine spinal cord. Neuropeptides, 4(2):157-166.
8.Minamino N, Kangawa K, Matsuo H (1984). Neuromedin C: a bombesin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun., 119(1):14-20.
9.Raddatz R, Wilson AE, Artymyshyn R, Bonini JA, Borowsky B, Boteju LW, Zhou S, Kouranova EV, Nagorny R, Guevarra MS, Dai M, Lerman GS, Vaysse PJ, Branchek TA, Gerald C, Forray C, Adham N (2000). Identification and Characterization of Two Neuromedin U Receptors Differentially Expressed in Peripheral Tissues and the Central Nervous System. J. Biol. Chem., 275(42):32452-32459.
10. Paul J. Brighton, Philip G. Szekeres and Gary B. Willars (2004). Neuromedin U and Its Receptors: Structure, Function, and Physiological Roles. Pharmacol Rev., 56:231-248.
11. Benya RV, Wada E, Battey JF, Fathi Z, Wang LH, Mantey SA, Coy DH, Jensen RT(1997). Neuromedin B receptors retain functional expression when transfected into BALB 3T3 fibroblasts: analysis of binding, kinetics, stoichiometry, modulation by guanine nucleotide-binding proteins, and signal transduction and comparison with natively expressed receptors. Mol Pharmacol., 42(6):1058-1068.



For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Neuromedins, smooth-muscle-stimulating peptides, are commonly divided into four groups: bombesin-like, kassinin-like, neurotensin-like and neuromedins U. These neuropeptides and their receptors are localized to all components of the HPA axis, the only exemption seems to be neurokinin B, which is not detected in the adenohypophysis 1.
Related Peptides
Nine neuromedins (B, B-30, B-32, C, K, L, N, U-8 and U-25) thus far identified in porcine spinal cord as the smooth-muscle stimulating peptides, are classified into four families; B-(bombesin-like), K-(kassinine-like), N-(neurotensin-like) and U-groups 2.
Discovery
Minamino et al., identified Neuromedin B, K, L, C, B-32, B-30, U-8, U-25, in porcine spinal cord, between 1983 and 1985 3. In 2008, Mori et al., isolated Neuromedin S, a novel neuropeptide of 36 amino acids, from rat brain as an endogenous ligand for the orphan G protein-coupled receptors FM-3/GPR66 and FM-4/TGR-1, identified to date as type-1 and type-2 neuromedin U (NMU) receptors, respectively. The peptide was designated neuromedin S (NMS) because it is specifically expressed in the suprachiasmatic nucleus of the hypothalamus 4.
Structural characteristics
Porcine neuromedin K has been identified by microsequencing as: Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH24. The sequence thus determined has been confirmed by synthesis. Neuromedin K has been found to have not only a remarkable sequence homology to kassinin and substance P, but also a prompt stimulant activity on guinea-pig ileum in a manner similar to that of substance P, suggesting that neuromedin K may be involved in neural transmission 6.
Novel mammalian tachykinin, designated "neuromedin L", has been isolated from porcine spinal cord by using bioassay for a tachykinin-like effect on contractility of smooth muscle preparation from guinea pig ileum. By microsequencing, the peptide has been determined to be His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2. This structure has been confirmed by synthesis. Neuromedin L is found to elicit a prompt stimulant activity on guinea pig ileum in a manner similar to that of substance P, and to have remarkable sequence homology to kassinin as well as neuromedin K, which was earlier identified as a mammalian tachykinin. These facts suggest that neuromedin L may participate in neural transmission in the same manner as other members of the mammalian tachykinin family, such as substance P and neuromedin K 7.
Sequence analyses and syntheses revealed that neuromedin U-8 is a novel octapeptide with a C-terminal amide structure, while U-25 contains the U-8 sequence at its C-terminus, preceded by paired Arg residues, implicating their biosynthetic relationship. Their potent uterus stimulating activity and hypertensive effect, as well as their unique C-terminal amide structure are indicative of their specialized physiological function 5.
Neuromedin C was obtained from a side fraction of neuromedin B. It is another decapeptide that exhibits a potent stimulant effect on the smooth muscle preparation of rat uterus. By microsequencing and synthesis, the amino acid sequence of the peptide has been identified as: Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2. This peptide is found to be identical with the carboxy-terminal subsequence [18-27] of gastrin releasing peptide, and to display a potent contractile activity on rat uterus in the characteristic manner of bombesin. These facts strongly suggest that the peptide may be a neuromediator in the neural communication systems of mammals 8.
Neuromedin S is structurally related to Neuromedin U. These peptides share a C-terminal core structure4.
Mode of Action
Two structurally related, G-protein-coupled receptors, FM-3 and FM-4, are specific and functional receptors for neuromedin U, designated NMU1 and NMU2, respectively. NMU1 is expressed predominantly in peripheral tissues, whereas NMU2 is more highly expressed in the central nervous system 9. Functional screening assays suggest that NmU-R1 and NmU-R2 of human and rodent origin are able to mediate intracellular Ca2+ signaling with potency in the nanomolar range. Activation of either hNmU-R1 or hNmU-R2 is also able to stimulate the release of arachidonic acid, most likely through a Ca2+-dependent activation of phospholipase A2 10. The receptor that interacts with the mammalian bombesin-related peptide neuromedin B (NMB) is ubiquitous in the gastrointestinal tract and central nervous system. Activation of the receptor for NMB stimulates phospholipase C and increases intracellular Ca2+ 11.
Functions
Neuromedins exert a manifold effect on HPA axis, and their action on the adrenal suggests their involvement in the regulation of growth, structure and function of the adrenal cortex. Neuromedins may exert both direct and indirect effects on the adrenal cortex. Direct effect is proven by the stimulation of mineralo- and glucocorticoid output by isolated or cultured adrenocortical cells and by mobilisation of intracellular [Ca2+]i. Indirect effects, on the other hand, may be mediated by ACTH, arginine-vasopressin, angiotensin II, catecholamines or by other regulatory substances of medullary origin 1.
References
1.Malendowicz LK (1998). Role of neuromedins in the regulation of adrenocortical function. Horm Metab Res., 30(6-7):374-383.
2.Minamino N, Sudoh T, Kangawa K, Matsuo H (1985). Neuromedins: novel smooth-muscle stimulating peptides identified in porcine spinal cord. Peptides, 6(3):245-248.
3.Minamino N, Kangawa K, Matsuo H (1983). Neuromedin B: a novel bombesin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun., 114(2):541-548.
4.Mori K, Miyazato M, Kangawa K (2008). Neuromedin S: discovery and functions. Results Probl Cell Differ.,46:201-212.
5.Minamino N, Sudoh T, Kangawa K, Matsuo H (1985). Neuromedins: novel smooth-muscle stimulating peptides identified in porcine spinal cord. Peptides, 6(3):245-248.
6.Kangawa K, Minamino N, Fukuda A, Matsuo H (1983). Neuromedin K: a novel mammalian tachykinin identified in porcine spinal cord. Biochem Biophys Res Commun., 114(2):533-540.
7.Minamino N, Kangawa K, Fukuda A, Matsuo H (1984). Neuromedin L: a novel mammalian tachykinin identified in porcine spinal cord. Neuropeptides, 4(2):157-166.
8.Minamino N, Kangawa K, Matsuo H (1984). Neuromedin C: a bombesin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun., 119(1):14-20.
9.Raddatz R, Wilson AE, Artymyshyn R, Bonini JA, Borowsky B, Boteju LW, Zhou S, Kouranova EV, Nagorny R, Guevarra MS, Dai M, Lerman GS, Vaysse PJ, Branchek TA, Gerald C, Forray C, Adham N (2000). Identification and Characterization of Two Neuromedin U Receptors Differentially Expressed in Peripheral Tissues and the Central Nervous System. J. Biol. Chem., 275(42):32452-32459.
10. Paul J. Brighton, Philip G. Szekeres and Gary B. Willars (2004). Neuromedin U and Its Receptors: Structure, Function, and Physiological Roles. Pharmacol Rev., 56:231-248.
11. Benya RV, Wada E, Battey JF, Fathi Z, Wang LH, Mantey SA, Coy DH, Jensen RT(1997). Neuromedin B receptors retain functional expression when transfected into BALB 3T3 fibroblasts: analysis of binding, kinetics, stoichiometry, modulation by guanine nucleotide-binding proteins, and signal transduction and comparison with natively expressed receptors. Mol Pharmacol., 42(6):1058-1068.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Neuromedins
Definition
Neuromedins, smooth-muscle-stimulating peptides, are commonly divided into four groups: bombesin-like, kassinin-like, neurotensin-like and neuromedins U. These neuropeptides and their receptors are localized to all components of the HPA axis, the only exemption seems to be neurokinin B, which is not detected in the adenohypophysis 1.
Related Peptides
Nine neuromedins (B, B-30, B-32, C, K, L, N, U-8 and U-25) thus far identified in porcine spinal cord as the smooth-muscle stimulating peptides, are classified into four families; B-(bombesin-like), K-(kassinine-like), N-(neurotensin-like) and U-groups 2.
Discovery
Minamino et al., identified Neuromedin B, K, L, C, B-32, B-30, U-8, U-25, in porcine spinal cord, between 1983 and 1985 3. In 2008, Mori et al., isolated Neuromedin S, a novel neuropeptide of 36 amino acids, from rat brain as an endogenous ligand for the orphan G protein-coupled receptors FM-3/GPR66 and FM-4/TGR-1, identified to date as type-1 and type-2 neuromedin U (NMU) receptors, respectively. The peptide was designated neuromedin S (NMS) because it is specifically expressed in the suprachiasmatic nucleus of the hypothalamus 4.
Structural characteristics
Porcine neuromedin K has been identified by microsequencing as: Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH24. The sequence thus determined has been confirmed by synthesis. Neuromedin K has been found to have not only a remarkable sequence homology to kassinin and substance P, but also a prompt stimulant activity on guinea-pig ileum in a manner similar to that of substance P, suggesting that neuromedin K may be involved in neural transmission 6.
Novel mammalian tachykinin, designated "neuromedin L", has been isolated from porcine spinal cord by using bioassay for a tachykinin-like effect on contractility of smooth muscle preparation from guinea pig ileum. By microsequencing, the peptide has been determined to be His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2. This structure has been confirmed by synthesis. Neuromedin L is found to elicit a prompt stimulant activity on guinea pig ileum in a manner similar to that of substance P, and to have remarkable sequence homology to kassinin as well as neuromedin K, which was earlier identified as a mammalian tachykinin. These facts suggest that neuromedin L may participate in neural transmission in the same manner as other members of the mammalian tachykinin family, such as substance P and neuromedin K 7.
Sequence analyses and syntheses revealed that neuromedin U-8 is a novel octapeptide with a C-terminal amide structure, while U-25 contains the U-8 sequence at its C-terminus, preceded by paired Arg residues, implicating their biosynthetic relationship. Their potent uterus stimulating activity and hypertensive effect, as well as their unique C-terminal amide structure are indicative of their specialized physiological function 5.
Neuromedin C was obtained from a side fraction of neuromedin B. It is another decapeptide that exhibits a potent stimulant effect on the smooth muscle preparation of rat uterus. By microsequencing and synthesis, the amino acid sequence of the peptide has been identified as: Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2. This peptide is found to be identical with the carboxy-terminal subsequence [18-27] of gastrin releasing peptide, and to display a potent contractile activity on rat uterus in the characteristic manner of bombesin. These facts strongly suggest that the peptide may be a neuromediator in the neural communication systems of mammals 8.
Neuromedin S is structurally related to Neuromedin U. These peptides share a C-terminal core structure4.
Mode of Action
Two structurally related, G-protein-coupled receptors, FM-3 and FM-4, are specific and functional receptors for neuromedin U, designated NMU1 and NMU2, respectively. NMU1 is expressed predominantly in peripheral tissues, whereas NMU2 is more highly expressed in the central nervous system 9. Functional screening assays suggest that NmU-R1 and NmU-R2 of human and rodent origin are able to mediate intracellular Ca2+ signaling with potency in the nanomolar range. Activation of either hNmU-R1 or hNmU-R2 is also able to stimulate the release of arachidonic acid, most likely through a Ca2+-dependent activation of phospholipase A2 10. The receptor that interacts with the mammalian bombesin-related peptide neuromedin B (NMB) is ubiquitous in the gastrointestinal tract and central nervous system. Activation of the receptor for NMB stimulates phospholipase C and increases intracellular Ca2+ 11.
Functions
Neuromedins exert a manifold effect on HPA axis, and their action on the adrenal suggests their involvement in the regulation of growth, structure and function of the adrenal cortex. Neuromedins may exert both direct and indirect effects on the adrenal cortex. Direct effect is proven by the stimulation of mineralo- and glucocorticoid output by isolated or cultured adrenocortical cells and by mobilisation of intracellular [Ca2+]i. Indirect effects, on the other hand, may be mediated by ACTH, arginine-vasopressin, angiotensin II, catecholamines or by other regulatory substances of medullary origin 1.
References
1.Malendowicz LK (1998). Role of neuromedins in the regulation of adrenocortical function. Horm Metab Res., 30(6-7):374-383.
2.Minamino N, Sudoh T, Kangawa K, Matsuo H (1985). Neuromedins: novel smooth-muscle stimulating peptides identified in porcine spinal cord. Peptides, 6(3):245-248.
3.Minamino N, Kangawa K, Matsuo H (1983). Neuromedin B: a novel bombesin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun., 11
4(2):541-548. 4.Mori K, Miyazato M, Kangawa K (2008). Neuromedin S: discovery and functions. Results Probl Cell Differ.,46:201-212.
5.Minamino N, Sudoh T, Kangawa K, Matsuo H (1985). Neuromedins: novel smooth-muscle stimulating peptides identified in porcine spinal cord. Peptides, 6(3):245-248.
6.Kangawa K, Minamino N, Fukuda A, Matsuo H (1983). Neuromedin K: a novel mammalian tachykinin identified in porcine spinal cord. Biochem Biophys Res Commun., 114(2):533-540.
7.Minamino N, Kangawa K, Fukuda A, Matsuo H (1984). Neuromedin L: a novel mammalian tachykinin identified in porcine spinal cord. Neuropeptides, 4(2):157-166.
8.Minamino N, Kangawa K, Matsuo H (1984). Neuromedin C: a bombesin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun., 119(1):14-20.
9.Raddatz R, Wilson AE, Artymyshyn R, Bonini JA, Borowsky B, Boteju LW, Zhou S, Kouranova EV, Nagorny R, Guevarra MS, Dai M, Lerman GS, Vaysse PJ, Branchek TA, Gerald C, Forray C, Adham N (2000). Identification and Characterization of Two Neuromedin U Receptors Differentially Expressed in Peripheral Tissues and the Central Nervous System. J. Biol. Chem., 275(42):32452-32459.
10. Paul J. Brighton, Philip G. Szekeres and Gary B. Willars (2004). Neuromedin U and Its Receptors: Structure, Function, and Physiological Roles. Pharmacol Rev., 56:231-248.
11. Benya RV, Wada E, Battey JF, Fathi Z, Wang LH, Mantey SA, Coy DH, Jensen RT(1997). Neuromedin B receptors retain functional expression when transfected into BALB 3T3 fibroblasts: analysis of binding, kinetics, stoichiometry, modulation by guanine nucleotide-binding proteins, and signal transduction and comparison with natively expressed receptors. Mol Pharmacol., 42(6):1058-1068.

For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Neuromedins, smooth-muscle-stimulating peptides, are commonly divided into four groups: bombesin-like, kassinin-like, neurotensin-like and neuromedins U. These neuropeptides and their receptors are localized to all components of the HPA axis, the only exemption seems to be neurokinin B, which is not detected in the adenohypophysis 1.
Related Peptides
Nine neuromedins (B, B-30, B-32, C, K, L, N, U-8 and U-25) thus far identified in porcine spinal cord as the smooth-muscle stimulating peptides, are classified into four families; B-(bombesin-like), K-(kassinine-like), N-(neurotensin-like) and U-groups 2.
Discovery
Minamino et al., identified Neuromedin B, K, L, C, B-32, B-30, U-8, U-25, in porcine spinal cord, between 1983 and 1985 3. In 2008, Mori et al., isolated Neuromedin S, a novel neuropeptide of 36 amino acids, from rat brain as an endogenous ligand for the orphan G protein-coupled receptors FM-3/GPR66 and FM-4/TGR-1, identified to date as type-1 and type-2 neuromedin U (NMU) receptors, respectively. The peptide was designated neuromedin S (NMS) because it is specifically expressed in the suprachiasmatic nucleus of the hypothalamus 4.
Structural characteristics
Porcine neuromedin K has been identified by microsequencing as: Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH24. The sequence thus determined has been confirmed by synthesis. Neuromedin K has been found to have not only a remarkable sequence homology to kassinin and substance P, but also a prompt stimulant activity on guinea-pig ileum in a manner similar to that of substance P, suggesting that neuromedin K may be involved in neural transmission 6.
Novel mammalian tachykinin, designated "neuromedin L", has been isolated from porcine spinal cord by using bioassay for a tachykinin-like effect on contractility of smooth muscle preparation from guinea pig ileum. By microsequencing, the peptide has been determined to be His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2. This structure has been confirmed by synthesis. Neuromedin L is found to elicit a prompt stimulant activity on guinea pig ileum in a manner similar to that of substance P, and to have remarkable sequence homology to kassinin as well as neuromedin K, which was earlier identified as a mammalian tachykinin. These facts suggest that neuromedin L may participate in neural transmission in the same manner as other members of the mammalian tachykinin family, such as substance P and neuromedin K 7.
Sequence analyses and syntheses revealed that neuromedin U-8 is a novel octapeptide with a C-terminal amide structure, while U-25 contains the U-8 sequence at its C-terminus, preceded by paired Arg residues, implicating their biosynthetic relationship. Their potent uterus stimulating activity and hypertensive effect, as well as their unique C-terminal amide structure are indicative of their specialized physiological function 5.
Neuromedin C was obtained from a side fraction of neuromedin B. It is another decapeptide that exhibits a potent stimulant effect on the smooth muscle preparation of rat uterus. By microsequencing and synthesis, the amino acid sequence of the peptide has been identified as: Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2. This peptide is found to be identical with the carboxy-terminal subsequence [18-27] of gastrin releasing peptide, and to display a potent contractile activity on rat uterus in the characteristic manner of bombesin. These facts strongly suggest that the peptide may be a neuromediator in the neural communication systems of mammals 8.
Neuromedin S is structurally related to Neuromedin U. These peptides share a C-terminal core structure4.
Mode of Action
Two structurally related, G-protein-coupled receptors, FM-3 and FM-4, are specific and functional receptors for neuromedin U, designated NMU1 and NMU2, respectively. NMU1 is expressed predominantly in peripheral tissues, whereas NMU2 is more highly expressed in the central nervous system 9. Functional screening assays suggest that NmU-R1 and NmU-R2 of human and rodent origin are able to mediate intracellular Ca2+ signaling with potency in the nanomolar range. Activation of either hNmU-R1 or hNmU-R2 is also able to stimulate the release of arachidonic acid, most likely through a Ca2+-dependent activation of phospholipase A2 10. The receptor that interacts with the mammalian bombesin-related peptide neuromedin B (NMB) is ubiquitous in the gastrointestinal tract and central nervous system. Activation of the receptor for NMB stimulates phospholipase C and increases intracellular Ca2+ 11.
Functions
Neuromedins exert a manifold effect on HPA axis, and their action on the adrenal suggests their involvement in the regulation of growth, structure and function of the adrenal cortex. Neuromedins may exert both direct and indirect effects on the adrenal cortex. Direct effect is proven by the stimulation of mineralo- and glucocorticoid output by isolated or cultured adrenocortical cells and by mobilisation of intracellular [Ca2+]i. Indirect effects, on the other hand, may be mediated by ACTH, arginine-vasopressin, angiotensin II, catecholamines or by other regulatory substances of medullary origin 1.
References
1.Malendowicz LK (1998). Role of neuromedins in the regulation of adrenocortical function. Horm Metab Res., 30(6-7):374-383.
2.Minamino N, Sudoh T, Kangawa K, Matsuo H (1985). Neuromedins: novel smooth-muscle stimulating peptides identified in porcine spinal cord. Peptides, 6(3):245-248.
3.Minamino N, Kangawa K, Matsuo H (1983). Neuromedin B: a novel bombesin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun., 11
4(2):541-548. 4.Mori K, Miyazato M, Kangawa K (2008). Neuromedin S: discovery and functions. Results Probl Cell Differ.,46:201-212.
5.Minamino N, Sudoh T, Kangawa K, Matsuo H (1985). Neuromedins: novel smooth-muscle stimulating peptides identified in porcine spinal cord. Peptides, 6(3):245-248.
6.Kangawa K, Minamino N, Fukuda A, Matsuo H (1983). Neuromedin K: a novel mammalian tachykinin identified in porcine spinal cord. Biochem Biophys Res Commun., 114(2):533-540.
7.Minamino N, Kangawa K, Fukuda A, Matsuo H (1984). Neuromedin L: a novel mammalian tachykinin identified in porcine spinal cord. Neuropeptides, 4(2):157-166.
8.Minamino N, Kangawa K, Matsuo H (1984). Neuromedin C: a bombesin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun., 119(1):14-20.
9.Raddatz R, Wilson AE, Artymyshyn R, Bonini JA, Borowsky B, Boteju LW, Zhou S, Kouranova EV, Nagorny R, Guevarra MS, Dai M, Lerman GS, Vaysse PJ, Branchek TA, Gerald C, Forray C, Adham N (2000). Identification and Characterization of Two Neuromedin U Receptors Differentially Expressed in Peripheral Tissues and the Central Nervous System. J. Biol. Chem., 275(42):32452-32459.
10. Paul J. Brighton, Philip G. Szekeres and Gary B. Willars (2004). Neuromedin U and Its Receptors: Structure, Function, and Physiological Roles. Pharmacol Rev., 56:231-248.
11. Benya RV, Wada E, Battey JF, Fathi Z, Wang LH, Mantey SA, Coy DH, Jensen RT(1997). Neuromedin B receptors retain functional expression when transfected into BALB 3T3 fibroblasts: analysis of binding, kinetics, stoichiometry, modulation by guanine nucleotide-binding proteins, and signal transduction and comparison with natively expressed receptors. Mol Pharmacol., 42(6):1058-1068.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Neuromedin B Receptor Antagonist
Definition
Neuromedin B receptor (NMB-R, BB1) antagonist selectively blocks NMB-suppressed glucose intake in vivo. It is also a potent urotensin II receptor antagonist and displays affinity for somatostatin and µ-opioid receptors 1.
Related Peptides
BIM-23127 is a D-amino-acid substituted cyclo-somatostatin octapeptide analog that shares structural similarity with SB-710411, which functions as a competitive antagonist of the rat UT (rUT) receptor in the rat aorta and a full agonist at the recombinant hUT receptor 2.
Discovery
It was discovered and reported by Orbuch et al., in 1993, that certain substituted somatostatin (SS) analogues selectively antagonized the BB1 receptor compared to the BB2 receptor 3. The most potent analogue was cyclo-SS-octa [D-Nal-Cys-Tyr- D-Trp-Lys-Val-Cys-Nal-NH2], which had a 100-fold higher affinity for the BB1 receptor than the BB2 receptor (Ki -230 vs. 3000 nM). Unfortunately this analogue also interacted with high affinity with somatostatin receptors (IC50-0.80 nM) and mu opioid receptors (IC50-430 nM). Substitution of an ornithine for Lys greatly reduced the affinity for somatostatin receptors, and a related analogue, (BIM-23127), [D-Nal-Cys-Tyr- D-Trp-Orn-Val-Cys-Nal-NH2] inhibited NMB cell signaling in rat BB1 receptor transfected Rat-1 cells and selectively reversed NMB feeding suppression, but had no effect on the action of GRP. However, a recent study reports BIM-23127 also functions as a receptor antagonist of both human and rat urotensin-II receptors limiting its utility. Peptoid antagonists of BB1 have been described including PD 165929 and PD 168368, which have high affinity and selectivity for BB1. In a detailed comparison of bombesin receptors from different species, PD 168368 was found to have a similar high affinity (Ki-15-45 nM) for BB1 receptors from each species, a 30- to 60-fold lower affinity for the BB2 receptor from different species. It also inhibited NMB-stimulated cellular signaling in a competitive manner as well as inhibiting NMB-induced proliferation of rat C6 glioblastoma cells and NMB stimulation of NCI-H1299 lung cancer cell proliferation 1.
Structural Characteristics
BIM-23127: D-Nal-cyclo[Cys-Tyr-D-Trp-Orn-Val-Cys]-Nal-NH2.It is a D-amino-acid substituted cyclo-somatostatin octapeptide analog.
Mode of Action
BIM-23127 blocks NMB function by competitively binding to the NMB receptor2.
Functions
This selective NMB receptor antagonist completely blocked suppression of food intake produced by NMB but not by neuromedin C. This result suggested an independent role for NMB receptors in suppression of food intake by bombesin-like peptides and and demonstrated the utility of this group of antagonists for in vivo experiments4. Endogenous BN-like peptides, NMB and gastrin releasing peptides, have some roles for the modulation of learning and memory, and suggest that NMB/NMB-R pathway may also be involved in the memory acquisition and modulation as well as GRP/GRP-R pathway. NMB receptor antagonists have been used to provide an insight into these studies5. Both GRP-10 and NMB evoked concentration-dependent contractions in circular strips of esophagus and fundus and in longitudinal strips of the duodenum. These contractions were tetrodotoxin and atropine-resistant. The potency of NMB in esophageal strips was 33 times higher than that of GRP-10. In esophageal muscle NMB-preferring receptor antagonists inhibited the contractile activity of bombesin-like peptides6.
References
1.Jensen RT, Battey JF, Spindel ER, Benya RV. (2008). International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, distribution, pharmacology, signaling and functions in normal and disease states. Pharmacol Rev., 60(1):1–42.
2.Herold CL, Behm DJ, Buckley PT, Foley JJ, Wixted WE, Sarau HM, Douglas SA.(2003). The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors. Br J Pharm., 139:203–207.
3.Orbuch M, Taylor JE, Coy DH, Mrozinski JE Jr, Mantey SA, Battey JF, Moreau JP, Jensen R(1993). Discovery of a novel class of neuromedin B receptor antagonists, substituted somatostatin analogues. Mol Pharmacol., 44(4):841-850.
4.Ladenheim EE, Taylor JE, Coy DH, Moran TH.(1994). Blockade of feeding inhibition by neuromedin B using a selective receptor antagonist. Eur.J.Pharmacol., 271(1):7-9.
5.Santo-Yamada Y, Yamada K, Wada E, Goto Y, Wada K. (2003). Blockade of bombesin-like peptide receptors impairs inhibitory avoidance learning in mice. Neurosci.Lett., 340(1):65-68.
6.Milusheva EA, Kortezova NI, Mizhorkova ZN, Papasova M, Coy DH, Bálint A, Vizi ES, Varga G. (1998). Role of Different Bombesin Receptor Subtypes Mediating Contractile Activity in Cat Upper Gastrointestinal Tract. Peptides, 19(3):549-56.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Neuromedin B receptor (NMB-R, BB1) antagonist selectively blocks NMB-suppressed glucose intake in vivo. It is also a potent urotensin II receptor antagonist and displays affinity for somatostatin and µ-opioid receptors 1.
Related Peptides
BIM-23127 is a D-amino-acid substituted cyclo-somatostatin octapeptide analog that shares structural similarity with SB-710411, which functions as a competitive antagonist of the rat UT (rUT) receptor in the rat aorta and a full agonist at the recombinant hUT receptor 2.
Discovery
It was discovered and reported by Orbuch et al., in 1993, that certain substituted somatostatin (SS) analogues selectively antagonized the BB1 receptor compared to the BB2 receptor 3. The most potent analogue was cyclo-SS-octa [D-Nal-Cys-Tyr- D-Trp-Lys-Val-Cys-Nal-NH2], which had a 100-fold higher affinity for the BB1 receptor than the BB2 receptor (Ki -230 vs. 3000 nM). Unfortunately this analogue also interacted with high affinity with somatostatin receptors (IC50-0.80 nM) and mu opioid receptors (IC50-430 nM). Substitution of an ornithine for Lys greatly reduced the affinity for somatostatin receptors, and a related analogue, (BIM-23127), [D-Nal-Cys-Tyr- D-Trp-Orn-Val-Cys-Nal-NH2] inhibited NMB cell signaling in rat BB1 receptor transfected Rat-1 cells and selectively reversed NMB feeding suppression, but had no effect on the action of GRP. However, a recent study reports BIM-23127 also functions as a receptor antagonist of both human and rat urotensin-II receptors limiting its utility. Peptoid antagonists of BB1 have been described including PD 165929 and PD 168368, which have high affinity and selectivity for BB1. In a detailed comparison of bombesin receptors from different species, PD 168368 was found to have a similar high affinity (Ki-15-45 nM) for BB1 receptors from each species, a 30- to 60-fold lower affinity for the BB2 receptor from different species. It also inhibited NMB-stimulated cellular signaling in a competitive manner as well as inhibiting NMB-induced proliferation of rat C6 glioblastoma cells and NMB stimulation of NCI-H1299 lung cancer cell proliferation 1.
Structural Characteristics
BIM-23127: D-Nal-cyclo[Cys-Tyr-D-Trp-Orn-Val-Cys]-Nal-NH2.It is a D-amino-acid substituted cyclo-somatostatin octapeptide analog.
Mode of Action
BIM-23127 blocks NMB function by competitively binding to the NMB receptor2.
Functions
This selective NMB receptor antagonist completely blocked suppression of food intake produced by NMB but not by neuromedin C. This result suggested an independent role for NMB receptors in suppression of food intake by bombesin-like peptides and and demonstrated the utility of this group of antagonists for in vivo experiments4. Endogenous BN-like peptides, NMB and gastrin releasing peptides, have some roles for the modulation of learning and memory, and suggest that NMB/NMB-R pathway may also be involved in the memory acquisition and modulation as well as GRP/GRP-R pathway. NMB receptor antagonists have been used to provide an insight into these studies5. Both GRP-10 and NMB evoked concentration-dependent contractions in circular strips of esophagus and fundus and in longitudinal strips of the duodenum. These contractions were tetrodotoxin and atropine-resistant. The potency of NMB in esophageal strips was 33 times higher than that of GRP-10. In esophageal muscle NMB-preferring receptor antagonists inhibited the contractile activity of bombesin-like peptides6.
References
1.Jensen RT, Battey JF, Spindel ER, Benya RV. (2008). International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, distribution, pharmacology, signaling and functions in normal and disease states. Pharmacol Rev., 60(1):1–42.
2.Herold CL, Behm DJ, Buckley PT, Foley JJ, Wixted WE, Sarau HM, Douglas SA.(2003). The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors. Br J Pharm., 139:203–207.
3.Orbuch M, Taylor JE, Coy DH, Mrozinski JE Jr, Mantey SA, Battey JF, Moreau JP, Jensen R(1993). Discovery of a novel class of neuromedin B receptor antagonists, substituted somatostatin analogues. Mol Pharmacol., 44(4):841-850.
4.Ladenheim EE, Taylor JE, Coy DH, Moran TH.(1994). Blockade of feeding inhibition by neuromedin B using a selective receptor antagonist. Eur.J.Pharmacol., 271(1):7-9.
5.Santo-Yamada Y, Yamada K, Wada E, Goto Y, Wada K. (2003). Blockade of bombesin-like peptide receptors impairs inhibitory avoidance learning in mice. Neurosci.Lett., 340(1):65-68.
6.Milusheva EA, Kortezova NI, Mizhorkova ZN, Papasova M, Coy DH, Bálint A, Vizi ES, Varga G. (1998). Role of Different Bombesin Receptor Subtypes Mediating Contractile Activity in Cat Upper Gastrointestinal Tract. Peptides, 19(3):549-56.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Kinetensin and Fragments
Definition
Kinetensin is a nanopeptide, originally isolated from pepsin-treated plasma that shares some sequence homology with the C-teminal end of neurotensin. Endogenous neurotensin-like peptide originally isolated from pepsin-treated human plasma. Kinetensin induces histamine release from rat peritoneal mast cells in vitro. Alternative name is Neurotensin-related peptide.
Discovery
Mogard et al., in 1986 isolated a novel nanopeptide with neurotensin-like immunoreactivity from pepsin-treated human plasma by dialysis, ion-exchange chromatography and high performance reversed-phase liquid chromatography. The amino acid sequence was determined by automated gas-phase. Sequence homology with human serum albumin and with the biologically active peptides neurotensin and angiotensin was demonstrated. They proposed the name for this peptide kinetensin 1.
Structural Characteristics
Using a radioimmunoassay toward the COOH-terminal region of neurotensin, an immunoreactive and biologically active neurotensin-related peptide (NRP) was isolated from pepsin-treated fractions of bovine, canine, human, and rat plasma. Bovine NRP was identified as H-Ile-Ala-Arg-Arg-His-Pro-Tyr-Phe- Leu-OH, which is similar in structure to both neurotensin and angiotensin I. Canine and human NRP also had the above amino acid composition, whereas that obtained from rat plasma had valine substituted for isoleucine. The isolated peptides show an amino acid sequence homology to neurotensin and an ability to register in both radioreceptor and bioassays. Using V8 protease, glutamyl residues were shown to lie within 3-4 amino acids of each end of NRP, as also occurs for the related segmenitns albumin. These results suggest that a subset of albumin-related protein(s) could serve as precursor(s) to biologically active neurotensin-related peptide 2.
Mode of Action
Carraway et al., in 1987 isolated human and canine NRP from pepsin-treated plasmas that were shown to increase vascular permeability when injected intra-dermally into rats and to release histamine from rat mast cells in vitro. The pure peptides also cross reacted very effectively at nanomolar concentrations in a radio-receptor assay for neurotensin. The proteins which liberated NRP upon pepsin treatment were purified about 7-fold and shown to behave like albumin during sodium dodecyl sulfate-polyacrylamide gel electrophoresis, isoelectric focusing, and high pressure liquid chromatography. The purified preparations which contain Kinetensin were found to react with anti-albumin antisera during immunodiffusion 2.
Based upon the ability of NRP to release histamine from mast cells and to increase cutaneous vascular permeability, NRP functions as an inflammatory mediator. In this regard, NRP could be formed locally in a manner similar to bradykinin 3, perhaps via the release or activation of acid proteases such as cathepsin D. It is interesting that the second phase of inflammation is thought to be initiated by the release of lysosomal enzymes from phagocytes 4 and that acid protease activity in skin is elevated during an inflammatory response 5.
NRP derived from albumin-related protein is utilized as a modulator of above functions as well. Kinetensin was rapidly metabolized, approximately 200-fold more rapidly than neurotensin. The majority of the metabolism occurred in the circulation demonstrated both in vivo and in vitro. The lung and gut also clear kinetensin. Inhibition of converting enzyme, present in highest concentration in the lung, abolished lung clearance but was without effect on kinetensin metabolism by the gut or in the general circulation 6.Functions
A broad spectrum of biologic effects have been noted for Kinetensin, including effects on the endocrine, cardiovascular, digestive, and reticuloendothelial systems as well as on temperature regulation, nociception, and behavior . NRP is homologous to albumin, particularly to the segment between residues 137 and 149. Six of its 13 residues were identical and 3 were chemically similar to those in albumin, suggesting that albumin and the precursor to neurotensin may have evolved from a common ancestor. Extrapolating from the accepted mutation rate for albumin, one would calculate that this may have taken place before the evolution of vertebrates (about 500 million years ago). During its evolution, albumin has undergone several gene-triplication events, giving rise to at least three major domains in the molecule. Interestingly, the regions within two of these domains, which show partial homologies to neurotensin, are thought to participate in the binding of fatty acids and steroids. These sequence relationships are noteworthy in view of the suggested roles for neurotensin in the regulation of fat digestion, lipid absorption, and blood flow 6.
References
1.Mogard MH, Kobayashi R, Chen CF, Lee TD, Reeve J Jr, Shively JE, Walsh JH (1986). The amino acid sequence of kinetensin, a novel peptide isolated from pepsin-treated human plasma: homology with human serum albumin, neurotensin and angiotensin. Biochem.Biophys.Res.Comm., 136(3):983-988.
2.Carraway RE, Mitra SP, Cochrane DE.(1987). Structure of a biologically active neurotensin-related peptide obtained from pepsin-treated albumin(s). J.Biol.Chem., 262(13):5968-5973.
3.Regoli D, Barabé J.(1980). Pharmacology of bradykinin and related kinins. Pharmacol. Rev., 32(1):1-46.
4.Hoffstein S, Goldstein IM, Weissmann G. (1977). Role of microtubule assembly in lysosomal enzyme secretion from human polymorphonuclear leukocytes. A reevaluation. J Cell Biol., 73(1):242-256. .
5.Lazarus GS (1974). The role of neutral proteinase and cathepsin D in turpentine-induced inflammation. J. Inuest. Derm,. 62(4):367-371.
6.Read D, Shulkes A, Fletcher D, Hardy K (1993). Pharmacokinetics and biological activity of kinetensin in conscious sheep. Journal Inflammation Research., 38(1-2):231-239.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Kinetensin is a nanopeptide, originally isolated from pepsin-treated plasma that shares some sequence homology with the C-teminal end of neurotensin. Endogenous neurotensin-like peptide originally isolated from pepsin-treated human plasma. Kinetensin induces histamine release from rat peritoneal mast cells in vitro. Alternative name is Neurotensin-related peptide.
Discovery
Mogard et al., in 1986 isolated a novel nanopeptide with neurotensin-like immunoreactivity from pepsin-treated human plasma by dialysis, ion-exchange chromatography and high performance reversed-phase liquid chromatography. The amino acid sequence was determined by automated gas-phase. Sequence homology with human serum albumin and with the biologically active peptides neurotensin and angiotensin was demonstrated. They proposed the name for this peptide kinetensin 1.
Structural Characteristics
Using a radioimmunoassay toward the COOH-terminal region of neurotensin, an immunoreactive and biologically active neurotensin-related peptide (NRP) was isolated from pepsin-treated fractions of bovine, canine, human, and rat plasma. Bovine NRP was identified as H-Ile-Ala-Arg-Arg-His-Pro-Tyr-Phe- Leu-OH, which is similar in structure to both neurotensin and angiotensin I. Canine and human NRP also had the above amino acid composition, whereas that obtained from rat plasma had valine substituted for isoleucine. The isolated peptides show an amino acid sequence homology to neurotensin and an ability to register in both radioreceptor and bioassays. Using V8 protease, glutamyl residues were shown to lie within 3-4 amino acids of each end of NRP, as also occurs for the related segmenitns albumin. These results suggest that a subset of albumin-related protein(s) could serve as precursor(s) to biologically active neurotensin-related peptide 2.
Mode of Action
Carraway et al., in 1987 isolated human and canine NRP from pepsin-treated plasmas that were shown to increase vascular permeability when injected intra-dermally into rats and to release histamine from rat mast cells in vitro. The pure peptides also cross reacted very effectively at nanomolar concentrations in a radio-receptor assay for neurotensin. The proteins which liberated NRP upon pepsin treatment were purified about 7-fold and shown to behave like albumin during sodium dodecyl sulfate-polyacrylamide gel electrophoresis, isoelectric focusing, and high pressure liquid chromatography. The purified preparations which contain Kinetensin were found to react with anti-albumin antisera during immunodiffusion 2.
Based upon the ability of NRP to release histamine from mast cells and to increase cutaneous vascular permeability, NRP functions as an inflammatory mediator. In this regard, NRP could be formed locally in a manner similar to bradykinin 3, perhaps via the release or activation of acid proteases such as cathepsin D. It is interesting that the second phase of inflammation is thought to be initiated by the release of lysosomal enzymes from phagocytes 4 and that acid protease activity in skin is elevated during an inflammatory response 5.
NRP derived from albumin-related protein is utilized as a modulator of above functions as well. Kinetensin was rapidly metabolized, approximately 200-fold more rapidly than neurotensin. The majority of the metabolism occurred in the circulation demonstrated both in vivo and in vitro. The lung and gut also clear kinetensin. Inhibition of converting enzyme, present in highest concentration in the lung, abolished lung clearance but was without effect on kinetensin metabolism by the gut or in the general circulation 6.Functions
A broad spectrum of biologic effects have been noted for Kinetensin, including effects on the endocrine, cardiovascular, digestive, and reticuloendothelial systems as well as on temperature regulation, nociception, and behavior . NRP is homologous to albumin, particularly to the segment between residues 137 and 149. Six of its 13 residues were identical and 3 were chemically similar to those in albumin, suggesting that albumin and the precursor to neurotensin may have evolved from a common ancestor. Extrapolating from the accepted mutation rate for albumin, one would calculate that this may have taken place before the evolution of vertebrates (about 500 million years ago). During its evolution, albumin has undergone several gene-triplication events, giving rise to at least three major domains in the molecule. Interestingly, the regions within two of these domains, which show partial homologies to neurotensin, are thought to participate in the binding of fatty acids and steroids. These sequence relationships are noteworthy in view of the suggested roles for neurotensin in the regulation of fat digestion, lipid absorption, and blood flow 6.
References
1.Mogard MH, Kobayashi R, Chen CF, Lee TD, Reeve J Jr, Shively JE, Walsh JH (1986). The amino acid sequence of kinetensin, a novel peptide isolated from pepsin-treated human plasma: homology with human serum albumin, neurotensin and angiotensin. Biochem.Biophys.Res.Comm., 136(3):983-988.
2.Carraway RE, Mitra SP, Cochrane DE.(1987). Structure of a biologically active neurotensin-related peptide obtained from pepsin-treated albumin(s). J.Biol.Chem., 262(13):5968-5973.
3.Regoli D, Barabé J.(1980). Pharmacology of bradykinin and related kinins. Pharmacol. Rev., 32(1):1-46.
4.Hoffstein S, Goldstein IM, Weissmann G. (1977). Role of microtubule assembly in lysosomal enzyme secretion from human polymorphonuclear leukocytes. A reevaluation. J Cell Biol., 73(1):242-256. .
5.Lazarus GS (1974). The role of neutral proteinase and cathepsin D in turpentine-induced inflammation. J. Inuest. Derm,. 62(4):367-371.
6.Read D, Shulkes A, Fletcher D, Hardy K (1993). Pharmacokinetics and biological activity of kinetensin in conscious sheep. Journal Inflammation Research., 38(1-2):231-239.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Pseudin Peptides and Analogs
Definition
Pseudin is a peptide derived from Pseudis paradoxa. Pseudins have shown to have some antimicrobial function.
Analogs
A study show that analogs of the peptide with increased cationicity and a-helicity were chemically synthesized by progressively substituting neutral and acidic amino acid residues on the hydrophilic face of the a-helix by lysine. Analogs with up to three L-lysine substitutions showed increased potency against a range of gram-negative and gram-positive bacteria (up to 16-fold) whilst retaining low hemolytic activity. Increasing the number of l-lysines to four and five did not enhance antimicrobial potency further but increased hemolytic activity towards human erythrocytes. Increasing the hydrophobicity of pseudin-2, while maintaining the amphipathic character of the molecule, by substitution of neutral amino acids on the hydrophobic face of the a-helix by l-phenylalanine, had only minor effects on antimicrobial and hemolytic activities1.
Related Peptides
Pseudin-1, Pseudin-2, Pseudin-3, and Pseudin-4 are structurally related peptides with antimicrobial activity isolated from skin extracts of the South American paradoxical frog Pseudis paradoxa (Pseudidae) (Olson et al., 2001). Pseudins are a subfamily of the FSAP family (Frog Secreted Active Peptides) and belong to the class of cationic, amphipathic-helical antimicrobial peptides. Pseudin-2 is the most abundant and the most potent peptide2.
Structural Characteristics
Pseudin-2 is a naturally occurring 24 residues (GLNALKKVFQGIHEAIKLINHVQ-NH2) antimicrobial peptide and it has broad-spectrum antimicrobial activity and low cytotoxicity activity.
In a membrane-mimetic environment, the peptide exists in an amphipathic a-helical conformation. Circular dichroism (CD) studies showed that Pseudin-2 has a more amphipathic a-helical structure in negative liposome than in zwitterionic liposome. The peptide had no structural change in the increased salt concentration. It has been shown that salt did not affect peptide conformation but did influence membrane potential energy2.
Mode of Action
Pseudin-2 peptide is believed to exert its antimicrobial activity via formation of pores in the target cell membrane. A study of relationship between structure and mechanical action of pseudin-2 in microorganism and the interaction with various liposomes revealed that it causes perturbation of different liposomes and that the action of peptide is modulated to some extent by membrane lipid composition. In addition, pseudin-2 could form self-associated oligomeric structure in zwitterionic liposome and the release of fluorescent markers caused by pseudin-2 is size-dependent on liposome. It has been suggested that pseudin-2 forms pores via peptide oligomerization using the toroidal pore-forming mechanism in zwitterionic liposomes, whereas the barrel-stave model occurs in negatively charged liposomes.
Functions
Insulin-releasing properties of the frog skin peptide pseudin-2 and its [Lys18]-substituted analogue: A study was conducted to investigate the insulin-releasing properties and cytotoxicity of the peptide, together with selected analogues with increased cationicity and hydrophobicity. It has been found that at concentrations in the range 10(-9)-10(-6) m, pseudin-2, and its [Lys18], [Phe8], and [D-Lys3, D-Lys10, D-Lys14] derivatives, stimulated insulin release from the BRIN-BD11 clonal ß-cell line without increasing release of lactate dehydrogenase. Further, the [Lys18] analogue was the most potent (46% increase in insulin release at 10-9 M) and the most effective (215% increase in insulin release at 10-6 M). The more cationic [Lys3,Lys10,Lys14] and [Lys3,Lys10,Lys14,Lys21] analogues lacked insulinotropic action and the more hydrophobic [Phe16] analogue was cytotoxic at concentrations =10-7 m. Pseudin-2 and [Lys18]-pseudin-2 had no effect on intracellular calcium concentrations and stimulated insulin release in the absence of external calcium. [Lys18]-pseudin-2 (10 - 8 M) stimulated insulin release in the presence of diazoxide and verapamil. It has been suggested that pseudin-2 stimulates insulin secretion from BRIN-BD11 cells by a mechanism involving Ca2+-independent pathways and identify [Lys18]-pseudin-2 as a peptide that may have potential for development as a therapeutically valuable insulinotropic agent for the treatment of type 2 diabetes3.
Reference:
1. Pál T, Sonnevend A, Galadari S, Conlon JM. (2005). Design of potent, non-toxic antimicrobial agents based upon the structure of the frog skin peptide, Pseudin-2. Regul Pept., 129(1-3):85-91.
2. Olson L 3rd, Soto AM, Knoop FC, Conlon JM. (2001). Pseudin-2: an antimicrobial peptide with low hemolytic activity from the skin of the paradoxical frog. Biochem Biophys Res Commun., 288(4):1001-1005.
3. Abdel-Wahab YH, Power GJ, Ng MT, Flatt PR, Conlon JM. (2008). Insulin-releasing properties of the frog skin peptide pseudin-2 and its [Lys18]-substituted analogue. Biol Chemy., 389(2):143-148.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Pseudin is a peptide derived from Pseudis paradoxa. Pseudins have shown to have some antimicrobial function.
Analogs
A study show that analogs of the peptide with increased cationicity and a-helicity were chemically synthesized by progressively substituting neutral and acidic amino acid residues on the hydrophilic face of the a-helix by lysine. Analogs with up to three L-lysine substitutions showed increased potency against a range of gram-negative and gram-positive bacteria (up to 16-fold) whilst retaining low hemolytic activity. Increasing the number of l-lysines to four and five did not enhance antimicrobial potency further but increased hemolytic activity towards human erythrocytes. Increasing the hydrophobicity of pseudin-2, while maintaining the amphipathic character of the molecule, by substitution of neutral amino acids on the hydrophobic face of the a-helix by l-phenylalanine, had only minor effects on antimicrobial and hemolytic activities1.
Related Peptides
Pseudin-1, Pseudin-2, Pseudin-3, and Pseudin-4 are structurally related peptides with antimicrobial activity isolated from skin extracts of the South American paradoxical frog Pseudis paradoxa (Pseudidae) (Olson et al., 2001). Pseudins are a subfamily of the FSAP family (Frog Secreted Active Peptides) and belong to the class of cationic, amphipathic-helical antimicrobial peptides. Pseudin-2 is the most abundant and the most potent peptide2.
Structural Characteristics
Pseudin-2 is a naturally occurring 24 residues (GLNALKKVFQGIHEAIKLINHVQ-NH2) antimicrobial peptide and it has broad-spectrum antimicrobial activity and low cytotoxicity activity.
In a membrane-mimetic environment, the peptide exists in an amphipathic a-helical conformation. Circular dichroism (CD) studies showed that Pseudin-2 has a more amphipathic a-helical structure in negative liposome than in zwitterionic liposome. The peptide had no structural change in the increased salt concentration. It has been shown that salt did not affect peptide conformation but did influence membrane potential energy2.
Mode of Action
Pseudin-2 peptide is believed to exert its antimicrobial activity via formation of pores in the target cell membrane. A study of relationship between structure and mechanical action of pseudin-2 in microorganism and the interaction with various liposomes revealed that it causes perturbation of different liposomes and that the action of peptide is modulated to some extent by membrane lipid composition. In addition, pseudin-2 could form self-associated oligomeric structure in zwitterionic liposome and the release of fluorescent markers caused by pseudin-2 is size-dependent on liposome. It has been suggested that pseudin-2 forms pores via peptide oligomerization using the toroidal pore-forming mechanism in zwitterionic liposomes, whereas the barrel-stave model occurs in negatively charged liposomes.
Functions
Insulin-releasing properties of the frog skin peptide pseudin-2 and its [Lys18]-substituted analogue: A study was conducted to investigate the insulin-releasing properties and cytotoxicity of the peptide, together with selected analogues with increased cationicity and hydrophobicity. It has been found that at concentrations in the range 10(-9)-10(-6) m, pseudin-2, and its [Lys18], [Phe8], and [D-Lys3, D-Lys10, D-Lys14] derivatives, stimulated insulin release from the BRIN-BD11 clonal ß-cell line without increasing release of lactate dehydrogenase. Further, the [Lys18] analogue was the most potent (46% increase in insulin release at 10-9 M) and the most effective (215% increase in insulin release at 10-6 M). The more cationic [Lys3,Lys10,Lys14] and [Lys3,Lys10,Lys14,Lys21] analogues lacked insulinotropic action and the more hydrophobic [Phe16] analogue was cytotoxic at concentrations =10-7 m. Pseudin-2 and [Lys18]-pseudin-2 had no effect on intracellular calcium concentrations and stimulated insulin release in the absence of external calcium. [Lys18]-pseudin-2 (10 - 8 M) stimulated insulin release in the presence of diazoxide and verapamil. It has been suggested that pseudin-2 stimulates insulin secretion from BRIN-BD11 cells by a mechanism involving Ca2+-independent pathways and identify [Lys18]-pseudin-2 as a peptide that may have potential for development as a therapeutically valuable insulinotropic agent for the treatment of type 2 diabetes3.
Reference:
1. Pál T, Sonnevend A, Galadari S, Conlon JM. (2005). Design of potent, non-toxic antimicrobial agents based upon the structure of the frog skin peptide, Pseudin-2. Regul Pept., 129(1-3):85-91.
2. Olson L 3rd, Soto AM, Knoop FC, Conlon JM. (2001). Pseudin-2: an antimicrobial peptide with low hemolytic activity from the skin of the paradoxical frog. Biochem Biophys Res Commun., 288(4):1001-1005.
3. Abdel-Wahab YH, Power GJ, Ng MT, Flatt PR, Conlon JM. (2008). Insulin-releasing properties of the frog skin peptide pseudin-2 and its [Lys18]-substituted analogue. Biol Chemy., 389(2):143-148.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Pseudin Peptides and Analogs
Definition
Pseudin is a peptide derived from Pseudis paradoxa. Pseudins have shown to have some antimicrobial function.
Analogs
A study show that analogs of the peptide with increased cationicity and a-helicity were chemically synthesized by progressively substituting neutral and acidic amino acid residues on the hydrophilic face of the a-helix by lysine. Analogs with up to three L-lysine substitutions showed increased potency against a range of gram-negative and gram-positive bacteria (up to 16-fold) whilst retaining low hemolytic activity. Increasing the number of l-lysines to four and five did not enhance antimicrobial potency further but increased hemolytic activity towards human erythrocytes. Increasing the hydrophobicity of pseudin-2, while maintaining the amphipathic character of the molecule, by substitution of neutral amino acids on the hydrophobic face of the a-helix by l-phenylalanine, had only minor effects on antimicrobial and hemolytic activities1.
Related Peptides
Pseudin-1, Pseudin-2, Pseudin-3, and Pseudin-4 are structurally related peptides with antimicrobial activity isolated from skin extracts of the South American paradoxical frog Pseudis paradoxa (Pseudidae) (Olson et al., 2001). Pseudins are a subfamily of the FSAP family (Frog Secreted Active Peptides) and belong to the class of cationic, amphipathic-helical antimicrobial peptides. Pseudin-2 is the most abundant and the most potent peptide2.
Structural Characteristics
Pseudin-2 is a naturally occurring 24 residues (GLNALKKVFQGIHEAIKLINHVQ-NH2) antimicrobial peptide and it has broad-spectrum antimicrobial activity and low cytotoxicity activity.
In a membrane-mimetic environment, the peptide exists in an amphipathic a-helical conformation. Circular dichroism (CD) studies showed that Pseudin-2 has a more amphipathic a-helical structure in negative liposome than in zwitterionic liposome. The peptide had no structural change in the increased salt concentration. It has been shown that salt did not affect peptide conformation but did influence membrane potential energy2.
Mode of Action
Pseudin-2 peptide is believed to exert its antimicrobial activity via formation of pores in the target cell membrane. A study of relationship between structure and mechanical action of pseudin-2 in microorganism and the interaction with various liposomes revealed that it causes perturbation of different liposomes and that the action of peptide is modulated to some extent by membrane lipid composition. In addition, pseudin-2 could form self-associated oligomeric structure in zwitterionic liposome and the release of fluorescent markers caused by pseudin-2 is size-dependent on liposome. It has been suggested that pseudin-2 forms pores via peptide oligomerization using the toroidal pore-forming mechanism in zwitterionic liposomes, whereas the barrel-stave model occurs in negatively charged liposomes.
Functions
Insulin-releasing properties of the frog skin peptide pseudin-2 and its [Lys18]-substituted analogue: A study was conducted to investigate the insulin-releasing properties and cytotoxicity of the peptide, together with selected analogues with increased cationicity and hydrophobicity. It has been found that at concentrations in the range 10(-9)-10(-6) m, pseudin-2, and its [Lys18], [Phe8], and [D-Lys3, D-Lys10, D-Lys14] derivatives, stimulated insulin release from the BRIN-BD11 clonal ß-cell line without increasing release of lactate dehydrogenase. Further, the [Lys18] analogue was the most potent (46% increase in insulin release at 10-9 M) and the most effective (215% increase in insulin release at 10-6 M). The more cationic [Lys3,Lys10,Lys14] and [Lys3,Lys10,Lys14,Lys21] analogues lacked insulinotropic action and the more hydrophobic [Phe16] analogue was cytotoxic at concentrations =10-7 m. Pseudin-2 and [Lys18]-pseudin-2 had no effect on intracellular calcium concentrations and stimulated insulin release in the absence of external calcium. [Lys18]-pseudin-2 (10 - 8 M) stimulated insulin release in the presence of diazoxide and verapamil. It has been suggested that pseudin-2 stimulates insulin secretion from BRIN-BD11 cells by a mechanism involving Ca2+-independent pathways and identify [Lys18]-pseudin-2 as a peptide that may have potential for development as a therapeutically valuable insulinotropic agent for the treatment of type 2 diabetes3.
Reference:
1. Pál T, Sonnevend A, Galadari S, Conlon JM. (2005). Design of potent, non-toxic antimicrobial agents based upon the structure of the frog skin peptide, Pseudin-2. Regul Pept., 129(1-3):85-91.
2. Olson L 3rd, Soto AM, Knoop FC, Conlon JM. (2001). Pseudin-2: an antimicrobial peptide with low hemolytic activity from the skin of the paradoxical frog. Biochem Biophys Res Commun., 288(4):1001-1005.
3. Abdel-Wahab YH, Power GJ, Ng MT, Flatt PR, Conlon JM. (2008). Insulin-releasing properties of the frog skin peptide pseudin-2 and its [Lys18]-substituted analogue. Biol Chemy., 389(2):143-148.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Pseudin is a peptide derived from Pseudis paradoxa. Pseudins have shown to have some antimicrobial function.
Analogs
A study show that analogs of the peptide with increased cationicity and a-helicity were chemically synthesized by progressively substituting neutral and acidic amino acid residues on the hydrophilic face of the a-helix by lysine. Analogs with up to three L-lysine substitutions showed increased potency against a range of gram-negative and gram-positive bacteria (up to 16-fold) whilst retaining low hemolytic activity. Increasing the number of l-lysines to four and five did not enhance antimicrobial potency further but increased hemolytic activity towards human erythrocytes. Increasing the hydrophobicity of pseudin-2, while maintaining the amphipathic character of the molecule, by substitution of neutral amino acids on the hydrophobic face of the a-helix by l-phenylalanine, had only minor effects on antimicrobial and hemolytic activities1.
Related Peptides
Pseudin-1, Pseudin-2, Pseudin-3, and Pseudin-4 are structurally related peptides with antimicrobial activity isolated from skin extracts of the South American paradoxical frog Pseudis paradoxa (Pseudidae) (Olson et al., 2001). Pseudins are a subfamily of the FSAP family (Frog Secreted Active Peptides) and belong to the class of cationic, amphipathic-helical antimicrobial peptides. Pseudin-2 is the most abundant and the most potent peptide2.
Structural Characteristics
Pseudin-2 is a naturally occurring 24 residues (GLNALKKVFQGIHEAIKLINHVQ-NH2) antimicrobial peptide and it has broad-spectrum antimicrobial activity and low cytotoxicity activity.
In a membrane-mimetic environment, the peptide exists in an amphipathic a-helical conformation. Circular dichroism (CD) studies showed that Pseudin-2 has a more amphipathic a-helical structure in negative liposome than in zwitterionic liposome. The peptide had no structural change in the increased salt concentration. It has been shown that salt did not affect peptide conformation but did influence membrane potential energy2.
Mode of Action
Pseudin-2 peptide is believed to exert its antimicrobial activity via formation of pores in the target cell membrane. A study of relationship between structure and mechanical action of pseudin-2 in microorganism and the interaction with various liposomes revealed that it causes perturbation of different liposomes and that the action of peptide is modulated to some extent by membrane lipid composition. In addition, pseudin-2 could form self-associated oligomeric structure in zwitterionic liposome and the release of fluorescent markers caused by pseudin-2 is size-dependent on liposome. It has been suggested that pseudin-2 forms pores via peptide oligomerization using the toroidal pore-forming mechanism in zwitterionic liposomes, whereas the barrel-stave model occurs in negatively charged liposomes.
Functions
Insulin-releasing properties of the frog skin peptide pseudin-2 and its [Lys18]-substituted analogue: A study was conducted to investigate the insulin-releasing properties and cytotoxicity of the peptide, together with selected analogues with increased cationicity and hydrophobicity. It has been found that at concentrations in the range 10(-9)-10(-6) m, pseudin-2, and its [Lys18], [Phe8], and [D-Lys3, D-Lys10, D-Lys14] derivatives, stimulated insulin release from the BRIN-BD11 clonal ß-cell line without increasing release of lactate dehydrogenase. Further, the [Lys18] analogue was the most potent (46% increase in insulin release at 10-9 M) and the most effective (215% increase in insulin release at 10-6 M). The more cationic [Lys3,Lys10,Lys14] and [Lys3,Lys10,Lys14,Lys21] analogues lacked insulinotropic action and the more hydrophobic [Phe16] analogue was cytotoxic at concentrations =10-7 m. Pseudin-2 and [Lys18]-pseudin-2 had no effect on intracellular calcium concentrations and stimulated insulin release in the absence of external calcium. [Lys18]-pseudin-2 (10 - 8 M) stimulated insulin release in the presence of diazoxide and verapamil. It has been suggested that pseudin-2 stimulates insulin secretion from BRIN-BD11 cells by a mechanism involving Ca2+-independent pathways and identify [Lys18]-pseudin-2 as a peptide that may have potential for development as a therapeutically valuable insulinotropic agent for the treatment of type 2 diabetes3.
Reference:
1. Pál T, Sonnevend A, Galadari S, Conlon JM. (2005). Design of potent, non-toxic antimicrobial agents based upon the structure of the frog skin peptide, Pseudin-2. Regul Pept., 129(1-3):85-91.
2. Olson L 3rd, Soto AM, Knoop FC, Conlon JM. (2001). Pseudin-2: an antimicrobial peptide with low hemolytic activity from the skin of the paradoxical frog. Biochem Biophys Res Commun., 288(4):1001-1005.
3. Abdel-Wahab YH, Power GJ, Ng MT, Flatt PR, Conlon JM. (2008). Insulin-releasing properties of the frog skin peptide pseudin-2 and its [Lys18]-substituted analogue. Biol Chemy., 389(2):143-148.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Proteolipid Proteins (PLPs)
Definition
Proteolipid protein (PLP), also named lipophilin, is the major structural protein of brain white matter. It accounts for more than 50% of myelin membrane proteins of the central nervous system (CNS) and is supposed to maintain the myelin structure and function.
Discovery
In 1951, it was shown that brain tissue and brain tumor tissue have been found to contain a new type of component - Proteolipides. PLPs are lipoproteins having as constituents a lipide moiety and a protein moiety, but, while other known lipoproteins are soluble in water or salt solutions, proteolipides are insoluble in water and soluble in chloroform- methanol mixtures; i.e., their solubilities are akin to those of lipides. It is to emphasize this special feature that the name proteolipides has been coined1.
Structural Characteristics
PLP consists of a 276-residue-long polypeptide chain with five strongly hydrophobic sequences of, linked by highly charged hydrophilic sequences. It has been propose that PLP is integrated into the lipid bilayer of myelin with the NH2 terminus and three positively charged hydrophilic loops oriented toward the extracytosolic side of the membrane, whereas one strongly negative hydrophilic loop and the positively charged COOH terminus cover the cytosolic side of the lipid bilayer. Basic myelinprotein remains protected against tryptic cleavage, which indicates its apposition to the cytosolic side of the membrane. These cleavage sites of trypsin support the suggested orientation of PLP in the myelin membrane and molecular arrangement2.
Mode of Action
PLP mediates winding and adhesion of phospholipid membranes but prevents their fusion: An experiment was conducted to investigate PLP’s putative adhesive function using purified PLP and reconstituted phospholipid vesicles made of either 100% phosphatidylcholine (PC), or a mixture of 92% PC and 8% phosphatidylserine (PS), by weight. PLP-induced changes in the phospholipid bilayer surfaces were directly examined by transmission electron microscopy. It was shown that, upon the introduction of PLP, larger lipid vesicles became smaller and unilamellar. At the PLP:lipid molar ratio of 1:20, vesicle membranes rolled onto themselves forming ‘croissant’-like structures that subsequently adhered to each other. The phenomena of PLP-induced bilayer rolling and adhesion were dependent on the concentration of PLP and the period of incubation, but were independent of the presence of calcium and types of phospholipids (PC or PC:PS). Furthermore, the presence of PLP in the lipid bilayers prevented the fusion of membranes. This shows that PLP can induce membrane ‘winding’ while preventing the fusion of adjacent lipid bilayers. Hence, provide direct evidence for PLP’s suspected function of membrane adhesion, and also suggest that PLP could potentially play a role in the formation of the myelin sheath.
Functions
Myelin proteolipid protein forms a complex with integrins and may participate in integrin receptor signaling in oligodendrocytes: A new role for the myelin proteolipid protein (PLP) has been identified, in studies showing PLP interaction with signaling proteins in oligodendrocytes. In particular, these studies suggest that the PLP protein may be involved in signaling through integrins in oligodendrocytes. Stimulation of muscarinic acetylcholine receptors on oligodendrocytes induced formation of a tripartite complex containing PLP, calreticulin, and a?-integrin. PLP interacted directly with the cytoplasmic domain of the a?-integrin. It has been shown that Complex formation was mediated by phospholipase C and Ca2+ binding to the high affinity binding site on calreticulin. Furthermore, this complex appears important for binding of fibronectin to oligodendrocytes. These data establish a novel function for PLP as a part of the integrin signaling complex in oligodendrocytes and suggest that neurotransmitter-mediated integrin receptor signaling may be involved in myelinogenesis4.
PLP and its role in the nervous system: A variety of mutations (missense mutations, deletions, and duplications) of the X-linked PLP gene cause the heterogeneous syndromes of Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia (SPG) in man and similar dysmyelinating disorders in a range of animal species.
Missense mutations cause a predicted alteration in primary structure of the encoded proteins and are generally associated with early onset of signs and generalised dysmyelination. The severity of the phenotype varies according to the particular codon involved. There is some evidence that the dysmyelination results from the altered protein acquiring a novel function deleterious to the oligodendrocyte's function. Transgenic mice carrying extra copies of the PLP gene provide a valid model of PMD/SPG due to gene duplication. Depending on the gene dosage, the phenotype can vary from early onset of severe and lethal dysmyelination through to a very late onset of a tract-specific demyelination and axonal degeneration5.
References
1.Folch J, Lees M (1951) Proteolipids, a new type of tissue lipoproteins. Their isolation from brain. J. Biol. Chem., 191(2):807-817.
2.Stoffel W, Hillen H, Giersiefen H. (1984) Structure and molecular arrangement of proteolipid protein of central nervous system myelin. Proc. Nati. Acad. Sci., 81(16):5012-5016.
3.Palaniyar N, Semotok JL, Wood DD, Moscarello MA, Harauz G. (1998). Human proteolipid protein (PLP) mediates winding and adhesion of phospholipid membranes but prevents their fusion. Biochim. Biophys. Acta., 1415 (1): 85-100.
4.Gudz TI, Schneider TE, Haas TA, Macklin WB. (2002). Myelin Proteolipid Protein Forms a Complex with Integrins and May Participate in Integrin Receptor Signaling in Oligodendrocytes. J Neurosci., 22 (17):7398-7407.
5.Griffiths I, Klugmann M, Anderson T, Thomson C, Vouyiouklis D, Nave KA (1998). Current concepts of PLP and its role in the nervous system. Microsc. Res. Tech., 41(5): 344-358

For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Proteolipid protein (PLP), also named lipophilin, is the major structural protein of brain white matter. It accounts for more than 50% of myelin membrane proteins of the central nervous system (CNS) and is supposed to maintain the myelin structure and function.
Discovery
In 1951, it was shown that brain tissue and brain tumor tissue have been found to contain a new type of component - Proteolipides. PLPs are lipoproteins having as constituents a lipide moiety and a protein moiety, but, while other known lipoproteins are soluble in water or salt solutions, proteolipides are insoluble in water and soluble in chloroform- methanol mixtures; i.e., their solubilities are akin to those of lipides. It is to emphasize this special feature that the name proteolipides has been coined1.
Structural Characteristics
PLP consists of a 276-residue-long polypeptide chain with five strongly hydrophobic sequences of, linked by highly charged hydrophilic sequences. It has been propose that PLP is integrated into the lipid bilayer of myelin with the NH2 terminus and three positively charged hydrophilic loops oriented toward the extracytosolic side of the membrane, whereas one strongly negative hydrophilic loop and the positively charged COOH terminus cover the cytosolic side of the lipid bilayer. Basic myelinprotein remains protected against tryptic cleavage, which indicates its apposition to the cytosolic side of the membrane. These cleavage sites of trypsin support the suggested orientation of PLP in the myelin membrane and molecular arrangement2.
Mode of Action
PLP mediates winding and adhesion of phospholipid membranes but prevents their fusion: An experiment was conducted to investigate PLP’s putative adhesive function using purified PLP and reconstituted phospholipid vesicles made of either 100% phosphatidylcholine (PC), or a mixture of 92% PC and 8% phosphatidylserine (PS), by weight. PLP-induced changes in the phospholipid bilayer surfaces were directly examined by transmission electron microscopy. It was shown that, upon the introduction of PLP, larger lipid vesicles became smaller and unilamellar. At the PLP:lipid molar ratio of 1:20, vesicle membranes rolled onto themselves forming ‘croissant’-like structures that subsequently adhered to each other. The phenomena of PLP-induced bilayer rolling and adhesion were dependent on the concentration of PLP and the period of incubation, but were independent of the presence of calcium and types of phospholipids (PC or PC:PS). Furthermore, the presence of PLP in the lipid bilayers prevented the fusion of membranes. This shows that PLP can induce membrane ‘winding’ while preventing the fusion of adjacent lipid bilayers. Hence, provide direct evidence for PLP’s suspected function of membrane adhesion, and also suggest that PLP could potentially play a role in the formation of the myelin sheath.
Functions
Myelin proteolipid protein forms a complex with integrins and may participate in integrin receptor signaling in oligodendrocytes: A new role for the myelin proteolipid protein (PLP) has been identified, in studies showing PLP interaction with signaling proteins in oligodendrocytes. In particular, these studies suggest that the PLP protein may be involved in signaling through integrins in oligodendrocytes. Stimulation of muscarinic acetylcholine receptors on oligodendrocytes induced formation of a tripartite complex containing PLP, calreticulin, and a?-integrin. PLP interacted directly with the cytoplasmic domain of the a?-integrin. It has been shown that Complex formation was mediated by phospholipase C and Ca2+ binding to the high affinity binding site on calreticulin. Furthermore, this complex appears important for binding of fibronectin to oligodendrocytes. These data establish a novel function for PLP as a part of the integrin signaling complex in oligodendrocytes and suggest that neurotransmitter-mediated integrin receptor signaling may be involved in myelinogenesis4.
PLP and its role in the nervous system: A variety of mutations (missense mutations, deletions, and duplications) of the X-linked PLP gene cause the heterogeneous syndromes of Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia (SPG) in man and similar dysmyelinating disorders in a range of animal species.
Missense mutations cause a predicted alteration in primary structure of the encoded proteins and are generally associated with early onset of signs and generalised dysmyelination. The severity of the phenotype varies according to the particular codon involved. There is some evidence that the dysmyelination results from the altered protein acquiring a novel function deleterious to the oligodendrocyte's function. Transgenic mice carrying extra copies of the PLP gene provide a valid model of PMD/SPG due to gene duplication. Depending on the gene dosage, the phenotype can vary from early onset of severe and lethal dysmyelination through to a very late onset of a tract-specific demyelination and axonal degeneration5.
References
1.Folch J, Lees M (1951) Proteolipids, a new type of tissue lipoproteins. Their isolation from brain. J. Biol. Chem., 191(2):807-817.
2.Stoffel W, Hillen H, Giersiefen H. (1984) Structure and molecular arrangement of proteolipid protein of central nervous system myelin. Proc. Nati. Acad. Sci., 81(16):5012-5016.
3.Palaniyar N, Semotok JL, Wood DD, Moscarello MA, Harauz G. (1998). Human proteolipid protein (PLP) mediates winding and adhesion of phospholipid membranes but prevents their fusion. Biochim. Biophys. Acta., 1415 (1): 85-100.
4.Gudz TI, Schneider TE, Haas TA, Macklin WB. (2002). Myelin Proteolipid Protein Forms a Complex with Integrins and May Participate in Integrin Receptor Signaling in Oligodendrocytes. J Neurosci., 22 (17):7398-7407.
5.Griffiths I, Klugmann M, Anderson T, Thomson C, Vouyiouklis D, Nave KA (1998). Current concepts of PLP and its role in the nervous system. Microsc. Res. Tech., 41(5): 344-358
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Subscribe to:
Posts (Atom)